Long-term follow-up of 18 patients with myelodysplastic syndromes responding to recombinant erythropoietin treatment
Data up to Jan 2025
Total Citations Per Year
Abstract
References (17)
International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes
1997 • 4,416 citations
Efficacy of erythropoietin in the myelodysplastic syndromes: a meta‐analysis of 205 patients from 17 studies
1995 • 359 citations
Erythroid response to treatment with G‐CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model
1997 • 317 citations
Treatment of Anemia in Myelodysplastic Syndromes With Granulocyte Colony-Stimulating Factor Plus Erythropoietin: Results From a Randomized Phase II Study and Long-Term Follow-Up of 71 Patients
1998 • 309 citations
Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy
1996 • 209 citations
Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes [see comments]
1991 • 144 citations
The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietin
1991 • 131 citations
Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes [see comments]
1991 • 117 citations
Improvement of anemia by recombinant erythropoietin in patients with myelodysplastic syndromes and aplastic anemia
1990 • 94 citations
Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer.
1998 • 83 citations
Treatment of myelodysplastic syndromes with recombinant human erythropoietin
1991 • 70 citations
Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes.
1993 • 57 citations
Serum levels of tumour necrosis factor-α predict response to recombinant human erythropoietin in patients with myelodysplastic syndrome
1997 • 46 citations
Low serum levels of tumor necrosis factor and interleukin-1 beta in myelodysplastic syndromes responsive to recombinant erythropoietin.
1994 • 43 citations
Serum levels of tumour necrosis factor-alpha predict response to recombinant human erythropoietin in patients with myelodysplastic syndrome.
1997 • 28 citations
A sequential erythropoietin and GM-CSF schedule offers clinical benefits in the treatment of anaemia in myelodysplastic syndromes
1996 • 25 citations
Efficacy of Recombinant Human Erythropoietin in the Treatment of Refractory Anemias Without Excess of Blasts in Myelodysplastic Syndromes
1994 • 19 citations